HHS unveiled new initiatives aimed at accelerating US clinical trials as competition from China and other regions intensifies. The “Surpass” program is designed to push clinical development toward a continuous learning model rather than disconnected trial phases, while ARPA-H is launching projects targeting faster enrollment, nationwide data infrastructure, and stronger patient engagement in research. The move is framed as a response to shifting global trial activity—HHS notes that China’s share of Phase 1 clinical trials surpassed the US in 2021 and that China registered more total clinical studies than the US in 2024. HHS argues the initiatives can reduce barriers that slow development timelines. Industry implications include stronger incentives for trials that adopt interoperable data infrastructure and enrollment designs, alongside more support for the use of qualified research institutions for early studies. For biotech leaders, the key is how the programs translate into practical regulatory and operational changes—particularly around trial design, data capture, and sponsor-resource allocation.